Baker Bros. Advisors Portfolio
ActivistBAKER BROS. ADVISORS LP 13F holdings · Q3 2026 vs Q2 2026
Why activist: 83 holdings, 13 effective · top 10 73% · turnover 12% a quarter · earnings yield -2.0% (median 2.9%) · 16 Schedule 13D filings, 51% of the book · 45 quarters of 13Fs
- 13F value
- $21.0bn+5.5% vs $20.0bn in Q2 2026
- Holdings
- 75 5 new · 6 sold out
- Top 10 weight
- 77.2% Largest: INCY 17.7%
- Bought est.
- $305m New positions and adds
- Sold est.
- $867m Trims and exits
- Quarter
- Q3 2026 Filed
Largest trades since Q2 2026
Estimated dollars: the change in shares times the quarter-end price the filing implies. Exits use last quarter's value.
| Action | Stock | Shares | Est. traded | Weight | Other gurus |
|---|---|---|---|---|---|
| Trimmed | CELCCelcuity Inc. | −39.2% | −$247m | 4.2% → 1.8% | 4 |
| Added | KODKodiak Sciences Inc. | +9.7% | +$184m | 3.9% → 9.8% | 3 |
| Trimmed | RVMDRevolution Medicines, Inc. | −7.0% | −$165m | 10.7% → 10.4% | 8 |
| Trimmed | IMVTImmunovant, Inc. | −49.0% | −$90m | 1.0% → 0.4% | 5 |
| Sold out | CRNXGBPCrinetics Pharmaceuticals, Inc. | −100.0% | −$88m | 0.4% → 0.0% | — |
| Sold out | ALMSAlumis Inc. | −100.0% | −$57m | 0.3% → 0.0% | — |
| Trimmed | STOKStoke Therapeutics, Inc. | −60.6% | −$53m | 0.5% → 0.2% | 4 |
| Trimmed | IONSIonis Pharmaceuticals, Inc. | −50.0% | −$46m | 0.8% → 0.2% | 4 |
| Added | CLDXCelldex Therapeutics, Inc. | +116.9% | +$45m | 0.2% → 0.4% | 3 |
| Sold out | VRDNViridian Therapeutics, Inc. | −100.0% | −$44m | 0.2% → 0.0% | — |
| Trimmed | ARWRArrowhead Pharmaceuticals, Inc. | −14.2% | −$19m | 0.8% → 0.5% | 4 |
| Sold out | SIONSionna Therapeutics, Inc. | −100.0% | −$18m | 0.1% → 0.0% | — |
| New | TRAXFirst Tracks Biotherapeutics, Inc. | New | +$17m | 0.0% → 0.1% | 1 |
| Trimmed | FTHFaeth Therapeutics, Inc. | −37.5% | −$14m | 0.2% → 0.1% | 4 |
| New | SCTXScribe Therapeutics Inc. | New | +$13m | 0.0% → 0.1% | 4 |
| New | FRNMFreenome, Inc. | New | +$13m | 0.0% → 0.1% | 4 |
| Added | ONCBeOne Medicines Ltd. | +0.3% | +$11m | 12.6% → 15.4% | 1 |
| Trimmed | CERSCerus Corporation | −63.5% | −$9.7m | 0.1% → 0.0% | 0 |
| Sold out | VSTMVerastem, Inc. | −100.0% | −$9.5m | 0.0% → 0.0% | — |
| Added | MPLTMapLight Therapeutics, Inc. | +219.9% | +$8.2m | 0.1% → 0.1% | 1 |
| Sold out | SGMTSagimet Biosciences Inc. | −100.0% | −$7.4m | 0.0% → 0.0% | — |
| New | QTTBQ32 Bio Inc. | New | +$4.5m | 0.0% → 0.0% | 3 |
| Added | DSGNDesign Therapeutics, Inc. | +11.6% | +$3.9m | 0.2% → 0.2% | 1 |
| Added | EVMNEvommune, Inc. | +45.7% | +$3.2m | 0.1% → 0.0% | 3 |
| Added | TARAProtara Therapeutics, Inc. | +89.8% | +$2.7m | 0.0% → 0.0% | 0 |
| Trimmed | NTLAIntellia Therapeutics, Inc. | −10.9% | −$1.2m | 0.1% → 0.0% | 0 |
| New | SKYESkye Bioscience, Inc. | New | +$317k | 0.0% → 0.0% | 0 |
| Added | INCYIncyte Corporation | 0.0% | +$39k | 17.5% → 17.7% | 1 |
| Added | ABCLAbCellera Biologics Inc. | 0.0% | +$15 | 1.3% → 2.3% | 0 |
All holdings 75 identified, plus $844m in securities without a listed ticker
Click a column to sort. Values are as reported at quarter-end, not today's prices.
| # | Stock | Shares | ||||
|---|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $3.7bn | 30,762,652 | 0.0% | 1 | |
| 2 | ONCBeOne Medicines Ltd. | $3.2bn | 8,832,335 | +0.3% | 1 | |
| 3 | RVMDRevolution Medicines, Inc. | $2.2bn | 10,637,318 | −7.0% | 8 | |
| 4 | KODKodiak Sciences Inc. | $2.1bn | 21,860,941 | +9.7% | 3 | |
| 5 | MDGLMadrigal Pharmaceuticals, Inc. | $1.1bn | 2,143,131 | Unchanged | 2 | |
| 6 | INSMInsmed Incorporated | $1.0bn | 8,796,111 | Unchanged | 7 | |
| 7 | KYMRKymera Therapeutics, Inc. | $968m | 8,657,242 | Unchanged | 3 | |
| 8 | ACADACADIA Pharmaceuticals Inc. | $865m | 42,912,904 | Unchanged | 2 | |
| 9 | GRALGRAIL, Inc. | $564m | 4,028,614 | Unchanged | 5 | |
| 10 | SMMTSummit Therapeutics Inc. | $554m | 32,786,348 | Unchanged | — | |
| 11 | RYTMRhythm Pharmaceuticals, Inc. | $534m | 5,604,483 | Unchanged | 3 | |
| 12 | PRAXPraxis Precision Medicines, Inc. | $511m | 1,753,198 | Unchanged | 5 | |
| 13 | ABCLAbCellera Biologics Inc. | $482m | 33,012,139 | 0.0% | — | |
| 14 | CELCCelcuity Inc. | $383m | 4,815,792 | −39.2% | 4 | |
| 15 | IDYAIDEAYA Biosciences, Inc. | $192m | 5,010,030 | Unchanged | 1 | |
| 16 | EWTXEdgewise Therapeutics, Inc. | $150m | 3,701,719 | Unchanged | 4 | |
| 17 | REPLReplimune Group, Inc. | $146m | 11,045,336 | Unchanged | 3 | |
| 18 | ARWRArrowhead Pharmaceuticals, Inc. | $112m | 1,709,053 | −14.2% | 4 | |
| 19 | NRIXNurix Therapeutics, Inc. | $110m | 4,658,556 | Unchanged | 3 | |
| 20 | IMVTImmunovant, Inc. | $94m | 2,770,377 | −49.0% | 5 | |
| 21 | CLDXCelldex Therapeutics, Inc. | $83m | 2,564,984 | +116.9% | 3 | |
| 22 | DNLIDenali Therapeutics Inc. | $77m | 3,734,336 | Unchanged | — | |
| 23 | DNTHDianthus Therapeutics, Inc. | $75m | 852,164 | Unchanged | 5 | |
| 24 | RAPPRapport Therapeutics, Inc. | $52m | 1,547,090 | Unchanged | 1 | |
| 25 | GLUEMonte Rosa Therapeutics, Inc. | $52m | 4,345,736 | Unchanged | 4 | |
| 26 | RLAYRelay Therapeutics, Inc. | $51m | 2,826,783 | Unchanged | 3 | |
| 27 | IONSIonis Pharmaceuticals, Inc. | $46m | 1,023,864 | −50.0% | 4 | |
| 28 | GPCRStructure Therapeutics Inc. | $45m | 1,432,529 | Unchanged | 5 | |
| 29 | ELVNEnliven Therapeutics, Inc. | $41m | 905,191 | Unchanged | 3 | |
| 30 | BCYCBicycle Therapeutics plc | $40m | 10,885,357 | Unchanged | — | |
| 31 | PRLDPrelude Therapeutics Inc. | $40m | 10,123,824 | Unchanged | 1 | |
| 32 | MIRMMirum Pharmaceuticals, Inc. | $38m | 445,975 | Unchanged | 8 | |
| 33 | DSGNDesign Therapeutics, Inc. | $38m | 2,988,144 | +11.6% | 1 | |
| 34 | STOKStoke Therapeutics, Inc. | $34m | 1,313,999 | −60.6% | 4 | |
| 35 | TRDAEntrada Therapeutics, Inc. | $32m | 5,072,730 | Unchanged | 2 | |
| 36 | NGNENeurogene Inc. | $28m | 991,691 | Unchanged | 1 | |
| 37 | XNCRXencor, Inc. | $27m | 1,102,106 | Unchanged | 4 | |
| 38 | FTHFaeth Therapeutics, Inc. | $24m | 803,425 | −37.5% | 4 | |
| 39 | ABSIAbsci Corporation | $23m | 2,134,803 | Unchanged | 2 | |
| 40 | IRONDisc Medicine, Inc. | $23m | 349,657 | Unchanged | 6 | |
| 41 | RCUSArcus Biosciences, Inc. | $22m | 844,816 | Unchanged | — | |
| 42 | GENBGenerate Biomedicines, Inc. | $21m | 1,423,602 | Unchanged | — | |
| 43 | TSHATaysha Gene Therapies, Inc. | $20m | 4,004,756 | Unchanged | 5 | |
| 44 | AKTSAktis Oncology, Inc. | $19m | 996,351 | Unchanged | 3 | |
| 45 | JBIOJade Biosciences, Inc. | $17m | 1,230,426 | Unchanged | 3 | |
| 46 | DBVTDBV Technologies S.A. | $17m | 1,461,425 | Unchanged | 2 | |
| 47 | TRAXFirst Tracks Biotherapeutics, Inc. | $17m | 472,932 | New | 1 | |
| 48 | PBLSParabilis Medicines, Inc. | $16m | 500,000 | Unchanged | 5 | |
| 49 | TECXTectonic Therapeutic, Inc. | $14m | 607,788 | Unchanged | 1 | |
| 50 | CYTKCytokinetics, Incorporated | $14m | 211,267 | Unchanged | 4 | |
| 51 | XENEXenon Pharmaceuticals Inc. | $14m | 370,208 | Unchanged | 4 | |
| 52 | CTMXCytomX Therapeutics, Inc. | $14m | 4,975,826 | Unchanged | 2 | |
| 53 | DYNDyne Therapeutics, Inc. | $13m | 813,449 | Unchanged | 5 | |
| 54 | SCTXScribe Therapeutics Inc. | $13m | 688,691 | New | 4 | |
| 55 | FRNMFreenome, Inc. | $13m | 794,908 | New | 4 | |
| 56 | MPLTMapLight Therapeutics, Inc. | $12m | 1,166,763 | +219.9% | 1 | |
| 57 | BNTXBioNTech SE | $12m | 119,743 | Unchanged | 2 | |
| 58 | SERASera Prognostics, Inc. | $11m | 5,498,170 | Unchanged | — | |
| 59 | EVMNEvommune, Inc. | $10m | 1,234,794 | +45.7% | 3 | |
| 60 | NTLAIntellia Therapeutics, Inc. | $10m | 829,053 | −10.9% | — | |
| 61 | AVLNAvalyn Pharma Inc. | $10m | 350,000 | Unchanged | 5 | |
| 62 | AVTXAvalo Therapeutics, Inc. | $8.4m | 550,000 | Unchanged | 5 | |
| 63 | TNGXTango Therapeutics, Inc. | $8.3m | 333,333 | Unchanged | 7 | |
| 64 | LBRXLB Pharmaceuticals Inc. | $7.7m | 200,000 | Unchanged | 3 | |
| 65 | TARAProtara Therapeutics, Inc. | $5.6m | 1,843,795 | +89.8% | — | |
| 66 | CERSCerus Corporation | $5.6m | 2,333,155 | −63.5% | — | |
| 67 | VTVTvTv Therapeutics, Inc. | $4.6m | 148,314 | Unchanged | — | |
| 68 | QTTBQ32 Bio Inc. | $4.5m | 547,945 | New | 3 | |
| 69 | EIKNEikon Therapeutics, Inc. | $4.5m | 555,555 | Unchanged | 1 | |
| 70 | IMNMImmunome, Inc. | $1.2m | 55,306 | Unchanged | — | |
| 71 | SANASana Biotechnology, Inc. | $905k | 310,483 | Unchanged | 1 | |
| 72 | TCRXTScan Therapeutics, Inc. | $876k | 2,784,792 | Unchanged | 1 | |
| 73 | ALGSAligos Therapeutics, Inc. | $468k | 83,055 | Unchanged | — | |
| 74 | SKYESkye Bioscience, Inc. | $317k | 196,905 | New | — | |
| 75 | TYRATyra Biosciences, Inc. | $232k | 10,607 | Unchanged | 5 |
Closest portfolios
Overlap is the weight two books have in common: for each shared stock, the smaller of the two weights, summed.
- Avoro Capital Advisors16.7%12 shared · MDGL, KYMR, RVMD, CELC
- Paradigm Biocapital Advisors16.2%7 shared · RVMD, INSM, EWTX, GPCR
- Bvf16.2%13 shared · RVMD, KYMR, GLUE, GPCR
- Farallon Capital Management13.8%10 shared · RVMD, GRAL, IMVT, PBLS
- Deerfield Management13.7%16 shared · RVMD, PRAX, CELC, IDYA
- Rtw Investments12.5%21 shared · INSM, CELC, MDGL, ACAD
- Perceptive Advisors11.6%19 shared · RYTM, PRAX, CELC, RVMD
- TCG Crossover Management6.1%18 shared · KOD, IMVT, DNTH, GLUE
- Ra Capital Management4.5%20 shared · RYTM, EWTX, PRLD, MIRM
- Novo Holdings3.9%9 shared · INSM, EWTX, CLDX, ELVN
Only here
The largest holdings no other tracked guru owns.
- SMMTSummit Therapeutics Inc.2.6%
- ABCLAbCellera Biologics Inc.2.3%
- DNLIDenali Therapeutics Inc.0.4%
- BCYCBicycle Therapeutics plc0.2%
- RCUSArcus Biosciences, Inc.0.1%
- GENBGenerate Biomedicines, Inc.0.1%
- SERASera Prognostics, Inc.0.1%
- NTLAIntellia Therapeutics, Inc.0.0%
- TARAProtara Therapeutics, Inc.0.0%
- CERSCerus Corporation0.0%
- VTVTvTv Therapeutics, Inc.0.0%
- IMNMImmunome, Inc.0.0%
A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.
Snapshot refreshed